What Can Move Roche’s Stock By 40% Next Year?

+29.53%
Upside
32.64
Market
42.28
Trefis
RHHBY: Roche logo
RHHBY
Roche

‘+40% To Roche’s Stock In 2016 If EBITDA Grows 5% & EV/EBITDA Multiple Expands 30%

 

+30% To EV/EBITDA Multiple If:

  • Drugs With Peak Sales ~ 20% Of Roche’s Sales ($10 Bil) Launched/Near Launch In 2016 (Historical Benchmark -> Table 1 At Bottom)
Relevant Articles
  1. Is Roche Stock Undervalued At $33?
  2. What’s Driving Roche Stock?
  3. Company Of The Day: Roche Holdings
  4. What’s Happening With Roche (RHHBY) Stock?
  5. What’s Next For Roche Stock?
  6. Should You Buy, Sell, Or Hold Roche Stock At $42?

 

Roche_Q13

 

Have more questions about Roche? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Roche

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology